Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development von Milligan, P A, Brown, M J, Marchant, B, Martin, S W, Graaf, P H, Benson, N, Nucci, G, Nichols, D J, Boyd, R A, Mandema, J W, Krishnaswami, S, Zwillich, S, Gruben, D, Anziano, R J, Stock, T C, Lalonde, R L

Volltext

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development von Milligan, P A, Brown, M J, Marchant, B, Martin, S W, van der Graaf, P H, Benson, N, Nucci, G, Nichols, D J, Boyd, R A, Mandema, J W, Krishnaswami, S, Zwillich, S, Gruben, D, Anziano, R J, Stock, T C, Lalonde, R L

Volltext

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a r... von Coombs, J H, Bloom, B J, Breedveld, F C, Fletcher, M P, Gruben, D, Kremer, J M, Burgos-Vargas, R, Wilkinson, B, Zerbini, C A F, Zwillich, S H

Volltext

AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A... von Harnett, J., Gerber, R., Gruben, D., Koenig, A., Chen, C.

Volltext

SAT0165 Tofacitinib versus Biologic Treatments in Moderate To Severe Rheumatoid Arthritis Patients Who Have Had An Inadequate Response To Nonbiologic Dmards: Systematic Literature... von Bergrath, E., Wallenstein, G., Gerbert, R., Gruben, D., Makin, C.

Volltext

Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis von Harnett, J., Wiederkehr, D., Gerber, R., Gruben, D., Koenig, A., Bourret, J.

Volltext

SAT0226 Early Experience with Tofacitinib: Treatment Patterns in Two us Healthcare Claims Databases von Harnett, J., Curtis, J., Gerber, R., Gruben, D., Koenig, A.

Volltext

THU0101 Real-World Evaluation of TNF Inhibitor Utilisation in Patients with Rheumatoid Arthritis in a us Claims Database von Harnett, J., Wiederkehr, D., Gerber, R., Gruben, D., Koenig, A., Bourret, J.

Volltext

THU0343 Modelling the Costs and Outcomes Associated with Sequence of Treatment with and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the US von Claxton, L., Taylor, M., Moynagh, D., Gruben, D., Wallenstein, G., Singh, A.

Volltext

THU0132 Comparative Effectiveness of TNFI and Tofacitinib Monotherapy in Clinical Practice: Results from Corrona Registry von Reed, G.W., Gerber, R.A., Shan, Y., Takiya, L., Dandreo, K.J., Gruben, D., Kremer, J.M., Wallenstein, G.

Volltext

AB0275 One-Year Treatment Patterns and Healthcare Resource Use Among Patients with Rheumatoid Arthritis Newly Initiating Treatment with Biologic Dmards von Harnett, J., Gerber, R., Gruben, D., Wiederkehr, D., Mahgoub, E.Y., Wallenstein, G., Koenig, A.

Volltext

SAT0220 Radiographic Progression in Modern RA Trials is Still a Robust Outcome: Results of Comprehensive Sensitivity Analysis in Two Phase 3 Trials with Tofacitinib von van der Heijde, D., Connell, C., Bradley, J., Gruben, D., Strengholt, S., Landewé, R.B.

Volltext

Tofacitinib versus Methotrexate in Rheumatoid Arthritis von Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

Volltext

Modelling The Costs and Outcomes Associated With Sequence Of Treatment With And Without Tofacitinib For The Treatment of Moderate to Severe Rheumatoid Arthritis In The Us von Claxton, L, Taylor, M, Moynagh, D, Gruben, D, Wallenstein, G, Singh, A

Volltext

OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Art... von Alten, R., Strand, V., Fleischmann, R., Koncz, T., Zwillich, S., Bradley, J., Gruben, D., Wilkinson, B., Krishnaswami, S., Wallenstein, G.

Volltext

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis von van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

Volltext

THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthriti... von Fleischmann, R.M., Krishnaswami, S., Gruben, D., Zwillich, S.H., Mebus, C., Bradley, J.D.

Volltext

FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease... von Vieira, M.C., Wallenstein, G.V., Bradley, J.D., Gruben, D., Koncz, T., Zwillich, S.H., Jansen, J.P.

Volltext

OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial von Genovese, M., van Vollenhoven, R., Wilkinson, B., Wang, L., Zwillich, S., Gruben, D., Benda, B., Jones, T., Bradley, J.

Volltext

THU0152 How should the primary endpoint be analysed in rheumatoid arthritis trials which mandate rescue prior to the clinical endpoint? Analysis of three phase 3 trials of tofaciti... von Fleischmann, R., Gruben, D., Krishnaswami, S., Zwillich, S.H., Benda, B., Mebus, C.A., Bradley, J.

Volltext